NCT07332000
Study arms updated — PHASE2
NCT07332000 • Phase 2
Enrollment 30→45 (50%) — PHASE2
NCT07332000 • Phase 2 • Enrollment 30→45 (+50%)
Primary endpoint removed: Biomarkers of immune activation and tumor burden — PHASE2
NCT07332000 • Phase 2